Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Looks like $3.75 is base now

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Dec 09, 2021 2:06pm

113 Views

Post# 34215479

RE:RE:Looks like $3.75 is base now

Do either of you Pandora and CASHEAGLE know how much cash Algernon has on hand?

Do either of you Pandora and CASHEAGLE know the actual guidelines for listing on Nasdaq?

Do either of you Pandora know how much money it will take to complete the Phase 1 DMT study for Stroke?

Do either of you Pandora and CASHEAGLE believe there will be a raise for funds at $5?

Do either of you Pandora and CASHEAGLE truly know the answer to any of the above and could you please provide a verification process, like links to your findings?

Thank you.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages